4 documents found, page 1 of 1
The Percentage of [−2]Pro–Prostate-Specific Antigen and the Prostate Health Ind...
Garrido, MM; Marta, JC; Bernardino, RM; Guerra, J; Fernandes, F; Pereira, MH; Ribeiro, R; Holdenrieder, S; Pinheiro, LC; Guimarães, JTContext.—: There is a need to avoid the overdiagnosis of prostate cancer (PCa) and to find more specific biomarkers. Objective.—: To evaluate the clinical utility of [-2]pro-prostate-specific antigen ([-2]proPSA) derivatives in detecting clinically significant PCa (csPCa) and to compare it with prostate-specific antigen (PSA) and with the percentage of free PSA (%fPSA). Design.—: Two hundred thirty-seven men (P...
The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Ind...
Garrido, MM; Marta, JC; Bernardino, RM; Guerra, J; Fernandes, F; Pereira, MH; Ribeiro, R; Holdenrieder, S; Pinheiro, LC; Guimarães, JTContext.— There is a need to avoid the overdiagnosis of prostate cancer (PCa) and to find more specific biomarkers. Objective.— To evaluate the clinical utility of [−2]pro–prostate-specific antigen ([−2]proPSA) derivatives in detecting clinically significant PCa (csPCa) and to compare it with prostate-specific antigen (PSA) and with the percentage of free PSA (%fPSA). Design.— Two hundred thirty-seven men (PSA:...
Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calib...
Garrido, MM; Marta, JC; Ribeiro, RM; Pinheiro, LC; Holdenrieder, S; Guimarães, JTBackground/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cob...
Tumour markers in prostate cancer: The post-prostate-specific antigen era
Garrido, MM; Bernardino, RM; Marta, JC; Holdenrieder, S; Guimarães, JTAlthough prostate-specific antigen-based prostate cancer screening had a positive impact in reducing prostate cancer mortality, it also led to overdiagnosis, overtreatment and a significant number of unnecessary biopsies. In the post-prostate-specific antigen era, new biomarkers have emerged that can complement the information given by prostate-specific antigen, towards a better cancer diagnostic specificity, a...